Invesco
ARQT icon

Invesco’s Arcutis Biotherapeutics ARQT Stock Holding History

Invesco’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.95M Buy
264,907
+125,064
+89% +$2.91M ﹤0.01% 2093
2026
Q1 		$3.29M Sell
139,843
-167,539
-55% -$4.28M ﹤0.01% 2337
2025
Q4 		$8.93M Buy
307,382
+114,430
+59% +$2.93M ﹤0.01% 1917
2025
Q3 		$3.64M Buy
192,952
+93,249
+94% +$1.47M ﹤0.01% 2372
2025
Q2 		$1.4M Sell
99,703
-1,229,251
-92% -$17.2M ﹤0.01% 2721
2025
Q1 		$20.8M Buy
1,328,954
+202,286
+18% +$2.85M ﹤0.01% 1420
2024
Q4 		$15.7M Buy
1,126,668
+188,184
+20% +$2.06M ﹤0.01% 1609
2024
Q3 		$8.73M Buy
938,484
+890
+0.1% +$8.78K ﹤0.01% 1913
2024
Q2 		$8.72M Buy
937,594
+65,250
+7% +$590K ﹤0.01% 1874
2024
Q1 		$8.64M Buy
872,344
+847,208
+3,370% +$6.32M ﹤0.01% 1904
2023
Q4 		$81.2K Buy
25,136
+63
+0.3% +$171 ﹤0.01% 3708
2023
Q3 		$133K Sell
25,073
-246
-1% -$2.09K ﹤0.01% 3681
2023
Q2 		$241K Buy
25,319
+1,289
+5% +$14.3K ﹤0.01% 3564
2023
Q1 		$264K Buy
24,030
+7,195
+43% +$104K ﹤0.01% 3542
2022
Q4 		$249K Sell
16,835
-1,786
-10% -$31.2K ﹤0.01% 3596
2022
Q3 		$356K Sell
18,621
-190,554
-91% -$4.32M ﹤0.01% 3436
2022
Q2 		$4.46M Buy
209,175
+197,916
+1,758% +$4.06M ﹤0.01% 2348
2022
Q1 		$217K Buy
11,259
+199
+2% +$3.37K ﹤0.01% 3757
2021
Q4 		$229K Sell
11,060
-2,054
-16% -$40.9K ﹤0.01% 3728
2021
Q3 		$314K Buy
13,114
+1,029
+9% +$23.5K ﹤0.01% 3635
2021
Q2 		$331K Buy
+12,085
New +$340K ﹤0.01% 3589

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Invesco's ARQT Position: Q2 2026 in Review

Invesco increased its Arcutis Biotherapeutics (ARQT) stake by 89% in Q2 2026, buying an estimated $2.91M and bringing the position to 264,907 shares worth $6.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Invesco first reported a position in ARQT in Q2 2021 and has held it in 21 quarters since. The position peaked at $20.8M in Q1 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Invesco held 264,907 shares of Arcutis Biotherapeutics worth $6.95M as of Q2 2026.
  • Invesco bought 125,064 Arcutis Biotherapeutics shares in Q2 2026, an estimated $2.91M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2093 holding.
  • Invesco first reported a position in Arcutis Biotherapeutics in Q2 2021 and has held it in 21 quarters since.
  • Invesco's Arcutis Biotherapeutics position peaked at $20.8M in Q1 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.